PE20090895A1 - TRIAZOLE DERIVATIVES AS JAK QUINASE INHIBITORS - Google Patents
TRIAZOLE DERIVATIVES AS JAK QUINASE INHIBITORSInfo
- Publication number
- PE20090895A1 PE20090895A1 PE2008001287A PE2008001287A PE20090895A1 PE 20090895 A1 PE20090895 A1 PE 20090895A1 PE 2008001287 A PE2008001287 A PE 2008001287A PE 2008001287 A PE2008001287 A PE 2008001287A PE 20090895 A1 PE20090895 A1 PE 20090895A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- pyrazole
- alkenyl
- methyl
- jak
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
REFERIDO A UN COMPUESTO DERIVADO DE TRIAZOL DE FORMULA (I): DONDE EL ANILLO A ES HETEROCICLILO OPCIONALMENTE SUSTITUIDO SOBRE EL C CON UNO O MAS R2; EL ANILLO B ES SELECCIONADO DE CARBOCICLO Y HETEROCICLILO OPCIONALMENTE SUSTITUIDO SOBRE EL C CON UNO O MAS R4; X ES -O-, -NH- Y -S-; R1 ES HALO, -CN, ALQUILO(C1-C6), ENTRE OTROS; R2 ES -CN, ALQUILO(C1-C6), ALQUENILO(C2-C6), ENTRE OTROS; R3 ES ALQUILO(C1-C6), ALQUENILO(C2-C6); ALQUINILO(C2-C6), ENTRE OTROS; R4 ES ALQUILO(C1-C6), ALQUENILO (C2-C6), CARBOCILILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (S)-N2-(1-(5-FLUOROPIRIDIN-2-IL)ETIL)-N4-(5-METIL-1H-PIRAZOL-3-IL)-6-(4-METILPIPERAZIN-1-IL)-1,3,5-TRIAZINA-2,4-DIAMINA, (S)-N2-(1-(5-FLUOROPIRIMIDIN-2-IL)ETIL)N4-(5-METIL-1H-PIRAZOL-3-IL)-6-MORFOLIN-1,3,5-TRIAZINA-2,4-DIAMINA, 4-(1-(5-FLUOROPIRIDIN-2-IL)ETOXI)-N-(5-METIL-1H-PIRAZOL-3-IL)-6-MORFOLIN-1,3,5-TRIAZIN-2-AMINA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA FORMULACION Y A UN METODO DE PREPARACION. DICHO COMPUESTO TIENE ACTIVIDAD INHIBITORIA DE JAK QUINASA Y ES UTIL EN EL TRATAMIENTO DE TRASTORNOS MIELOPROLIFERATIVOS Y EL CANCERREFERRING TO A COMPOUND DERIVED FROM TRIAZOLE OF FORMULA (I): WHERE THE RING A IS HETEROCYCLYL OPTIONALLY SUBSTITUTED ON THE C WITH ONE OR MORE R2; RING B IS SELECTED FROM CARBOCYCLE AND HETEROCYCLYL OPTIONALLY SUBSTITUTED ON C WITH ONE OR MORE R4; X IS -O-, -NH- AND -S-; R1 IS HALO, -CN, (C1-C6) ALKYL, AMONG OTHERS; R2 IS -CN, ALKYL (C1-C6), ALKENYL (C2-C6), AMONG OTHERS; R3 IS ALKYL (C1-C6), ALKENYL (C2-C6); ALKINYL (C2-C6), AMONG OTHERS; R4 IS ALKYL (C1-C6), ALKENYL (C2-C6), CARBOCILYL, AMONG OTHERS. PREFERRED COMPOUNDS ARE: (S) -N2- (1- (5-FLUOROPYRIDIN-2-IL) ETHYL) -N4- (5-METHYL-1H-PYRAZOLE-3-IL) -6- (4-METHYLPIPERAZIN-1- IL) -1,3,5-TRIAZINE-2,4-DIAMINE, (S) -N2- (1- (5-FLUOROPYRIMIDIN-2-IL) ETHYL) N4- (5-METHYL-1H-PYRAZOLE-3- IL) -6-MORPHOLIN-1,3,5-TRIAZINE-2,4-DIAMINE, 4- (1- (5-FLUOROPYRIDIN-2-IL) ETHOXY) -N- (5-METHYL-1H-PYRAZOLE-3 -IL) -6-MORFOLIN-1,3,5-TRIAZIN-2-AMINE, AMONG OTHERS. IT ALSO REFERS TO A FORMULATION AND A METHOD OF PREPARATION. SAID COMPOUND HAS JAK KINASE INHIBITORY ACTIVITY AND IS USEFUL IN THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS AND CANCER
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95315807P | 2007-07-31 | 2007-07-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20090895A1 true PE20090895A1 (en) | 2009-08-08 |
Family
ID=40304964
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2008001287A PE20090895A1 (en) | 2007-07-31 | 2008-07-31 | TRIAZOLE DERIVATIVES AS JAK QUINASE INHIBITORS |
Country Status (6)
Country | Link |
---|---|
AR (1) | AR069899A1 (en) |
CL (1) | CL2008002243A1 (en) |
PE (1) | PE20090895A1 (en) |
TW (1) | TW200906818A (en) |
UY (1) | UY31254A1 (en) |
WO (1) | WO2009016410A2 (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010105243A1 (en) | 2009-03-13 | 2010-09-16 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
WO2010144338A1 (en) * | 2009-06-08 | 2010-12-16 | Abraxis Bioscience, Llc | Triazine derivatives and their therapeutical applications |
EP2440053A4 (en) * | 2009-06-09 | 2012-10-31 | California Capital Equity Llc | Benzyl substituted triazine derivatives and their therapeutical applications |
NZ597379A (en) | 2009-06-29 | 2014-04-30 | Agios Pharmaceuticals Inc | Therapeutic compounds and compositions |
CA2793835C (en) | 2009-10-21 | 2021-07-20 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
HUE039269T2 (en) | 2011-05-03 | 2018-12-28 | Agios Pharmaceuticals Inc | Pyruvate kinase activators for use in therapy |
CN102827073A (en) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | Therapeutically active compositions and application methods thereof |
CN102827170A (en) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | Active treatment compositions and use method thereof |
US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
AR091858A1 (en) * | 2012-07-25 | 2015-03-04 | Sova Pharmaceuticals Inc | CISTATIONIN-g-LIASA INHIBITORS (CSE) |
MX365747B (en) | 2012-10-15 | 2019-06-12 | Agios Pharmaceuticals Inc | Therapeutic compounds and compositions. |
US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
WO2015003355A2 (en) * | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
CN105517996B (en) * | 2013-07-11 | 2019-03-26 | 安吉奥斯医药品有限公司 | Therapeutical active compound and its application method |
WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
US10376510B2 (en) | 2013-07-11 | 2019-08-13 | Agios Pharmaceuticals, Inc. | 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer |
US20150031627A1 (en) | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
KR20220070066A (en) | 2014-03-14 | 2022-05-27 | 아지오스 파마슈티컬스 아이엔씨. | Pharmaceutical compositions of therapeutically active compounds |
KR102542097B1 (en) | 2015-01-16 | 2023-06-09 | 바이엘 크롭사이언스 악티엔게젤샤프트 | Method for preparing 4-cyanopiperidine hydrochloride |
SI3307271T1 (en) | 2015-06-11 | 2023-11-30 | Agios Pharmaceuticals, Inc. | Methods of using pyruvate kinase activators |
BR122024000250A2 (en) | 2015-10-15 | 2024-02-27 | Les Laboratoires Servier | USE OF A MUTANT ISOCITRATE 1 (IDH1) DEHYDROGENASE INHIBITOR AND A DNA DEMETHYLATING AGENT |
UA123401C2 (en) | 2015-10-15 | 2021-03-31 | Аджиос Фармасьютікалз, Інк. | Combination therapy for treating malignancies |
US10980788B2 (en) | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
WO2019245910A1 (en) * | 2018-06-22 | 2019-12-26 | Aduro Biotech, Inc. | Triazine compounds and uses thereof |
CN109020951B (en) * | 2018-08-24 | 2020-06-02 | 大连理工大学 | Naphthalimide derivative containing trisubstituted cyanuric chloride and synthesis method and application thereof |
CN111454214B (en) * | 2020-05-27 | 2023-04-07 | 龙曦宁(上海)医药科技有限公司 | Synthetic method of 2-methoxy-1-pyrimidineethylamine hydrochloride |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2422377C (en) * | 2000-09-15 | 2010-04-13 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
EP1345922B1 (en) * | 2000-12-21 | 2006-05-31 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
WO2003078426A1 (en) * | 2002-03-15 | 2003-09-25 | Vertex Pharmaceuticals, Inc. | Azolylaminoazine as inhibitors of protein kinases |
EP1899323A2 (en) * | 2005-05-16 | 2008-03-19 | AstraZeneca AB | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors |
DK1945631T3 (en) * | 2005-10-28 | 2012-10-22 | Astrazeneca Ab | 4- (3-AMINOPYRAZOLE) PYRIMIDINE DERIVATIVES USED AS TYROSINKINASE INHIBITORS FOR CANCER TREATMENT |
-
2008
- 2008-07-29 TW TW097128670A patent/TW200906818A/en unknown
- 2008-07-30 UY UY31254A patent/UY31254A1/en unknown
- 2008-07-30 CL CL2008002243A patent/CL2008002243A1/en unknown
- 2008-07-31 WO PCT/GB2008/050644 patent/WO2009016410A2/en active Application Filing
- 2008-07-31 AR ARP080103333A patent/AR069899A1/en unknown
- 2008-07-31 PE PE2008001287A patent/PE20090895A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
TW200906818A (en) | 2009-02-16 |
CL2008002243A1 (en) | 2009-08-21 |
UY31254A1 (en) | 2009-04-30 |
WO2009016410A3 (en) | 2009-07-02 |
WO2009016410A2 (en) | 2009-02-05 |
AR069899A1 (en) | 2010-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20090895A1 (en) | TRIAZOLE DERIVATIVES AS JAK QUINASE INHIBITORS | |
PE20090773A1 (en) | DERIVATIVES OF MORPHOLINE PYRIMIDINE | |
PE20081362A1 (en) | MORPHOLINO PYRIMIDINE DERIVATIVES AS INHIBITORS OF mTOR KINASE AND PI3K | |
PE20141681A1 (en) | BTK INHIBITORS | |
PE20161066A1 (en) | PIPERIDINYL-INDOLE DERIVATIVES AS INHIBITORS OF COMPLEMENT FACTOR B AND USES OF THE SAME | |
PE20140934A1 (en) | DERIVATIVES OF PIRAZOLE | |
PE20150621A1 (en) | DERIVATIVES OF 2,4-DIAMINE-PYRIMIDINE N2, N4-DISUSTITUTED AS JAK3 INHIBITORS | |
PE20091573A1 (en) | HETEROCYCLIC DERIVATIVES OF UREA AS INHIBITORS OF DNA GIRASE AND / OR TOPOISOMERASE | |
PE20070808A1 (en) | COMPOUNDS DERIVED FROM ISOQUINOLINE AS INHIBITORS OF Rho-KINASE | |
PE20100138A1 (en) | MORPHOLIN PYRIMIDINE DERIVATIVES USED IN MTOR KINASE AND / OR PI3K-RELATED DISEASES | |
PE20131377A1 (en) | TRIAZINE-OXADIAZOLES | |
PE20081845A1 (en) | NEW AMINOPYRIMIDINE DERIVATIVES AS PLK1 INHIBITORS | |
NO20080675L (en) | P38-Map kinase inhibitors and methods for their use | |
PE20090210A1 (en) | COMPOUNDS DERIVED FROM PYRAZOLO PYRIMIDINE AS INHIBITORS OF JAK QUINASE | |
PE20130385A1 (en) | DERIVATIVES OF NAFT-2-ILACETIC ACID TO TREAT AIDS | |
PE20050681A1 (en) | PYRID [2,3-d] PYRIMIDINE-2,4-DIAMINES AS INHIBITORS OF PDE 2 | |
PE20090887A1 (en) | DERIVATIVES OF 1H-PYRAZOLE- [3,4-d] -PYRIMIDINE, 9H-PURINE AND 7H-PYRROL- [2,3-d] -PYRIMIDINE AS KINASE INHIBITORS P70 S6 | |
NZ591449A (en) | Picolinamide derivatives as kinase inhibitors | |
CR8744A (en) | THERAPEUTIC COMPOUNDS | |
PE20100087A1 (en) | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | |
AR059957A1 (en) | DERIVATIVES OF SPIROINDOLINONE, METHODS FOR THEIR PREPARATION, A PHARMACEUTICAL COMPOSITION CONTAINING THEM AND THEIR USE IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF CANCER. | |
PE20090816A1 (en) | PYRROLOPYRIMIDINONE DERIVATIVES AS BINDING AGENTS OF P2X3 RECEPTORS | |
PE20161236A1 (en) | TRIAZINE COMPOUND AND ITS USE FOR MEDICAL PURPOSES | |
PE20061106A1 (en) | DERIVATIVES OF 2- (4-OXO-4H-QUINAZOLIN-3-IL) ACETAMIDE | |
CL2012001366A1 (en) | Carboxamida |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |